Neurofibrillary Tangle-Induced Dementia in AD
AD 中神经原纤维缠结诱发的痴呆
基本信息
- 批准号:7036398
- 负责人:
- 金额:$ 11.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-03-01 至 2011-02-28
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs diseaseCD47 moleculechemical aggregateclinical researchdementiaentorhinal cortexfunctional /structural genomicsgene expression profilinghistopathologyhuman datahuman tissueimmunocytochemistryin situ hybridizationlaser capture microdissectionmolecular pathologyneural degenerationneurofibrillary tanglespatient oriented researchtau proteins
项目摘要
DESCRIPTION (provided by applicant): The candidate (Travis Dunckley) received his Ph.D. in Molecular and Cellular Biology from the University of Arizona in 2000, and has a history of productive research in genetics, molecular biology, and neurobiology. The candidate has expertise in molecular neurobiology and receptor biology. Recent work at the Translational Genomics Research Institute (TGen) has stimulated an interest in elucidating the etiology of neurodegenerative diseases, in particular, the mechanisms whereby neurofibrillary tangles (NFT) contribute to the neuronal cell death and dementia of Alzheimer's disease (AD). AD is a complex genetic disorder that is particularly amenable to genomic analysis via expression profiling. Using microarrays to uncover the molecular bases for NFT formation will require knowledge of: 1) genomics, 2) AD, 3) cell biology, areas in which the candidate has little background. The proposed plan will provide the candidate with a period of mentored research in order to gain expertise in these three areas. The expertise gained in this mentoring period will allow the candidate to attain his long-term goal of developing an independent, multidisciplinary research career in neuroscience, with an emphasis on neurodegenerative mechanisms. In the proposed study it is hypothesized that the CD47 signaling pathway contributes to abnormalities in tau metabolism, NFT formation, and neuronal cell death and dementia in AD. This hypothesis has been generated by stringent expression profiles and will be validated by adding more AD cases to the analysis and by showing that normal, non-demented controls have no involvement of the CD47 signaling cascade (Aim 1). Thereafter, we propose to validate this pathway at the mRNA, protein, and functional levels (Aim 2). Importantly, these experiments will identify numerous new and much needed potential targets for the treatment of AD. Dietrich Stephan, Ph.D. (mentor) will provide training in genomics and functional validation of microarray data. Joseph Rogers, Ph.D. (co-mentor) will provide training in AD and cell biological techniques. Additional resources and techniques in viral siRNA delivery and tau cell lines and phosphorylation assays will be received through continued ongoing collaborations (Dale Schenk and Michael Hutton). The many resources available to the candidate at TGen, in combination with the strong research programs of the mentor, co-mentor, and collaborators, will provide the candidate with the comprehensive training necessary to achieve his career goals and, hopefully, arrive at new therapeutic modalities for the largest cause of age-related dementia - Alzheimer's disease.
候选人(Travis Dunckley)于2000年获得亚利桑那大学分子与细胞生物学博士学位,在遗传学、分子生物学和神经生物学方面有着丰富的研究经验。该候选人具有分子神经生物学和受体生物学方面的专业知识。翻译基因组学研究所(TGen)最近的工作激发了人们对阐明神经退行性疾病病因的兴趣,特别是神经原纤维缠结(NFT)导致阿尔茨海默病(AD)的神经元细胞死亡和痴呆的机制。AD是一种复杂的遗传疾病,特别适合通过表达谱进行基因组分析。使用微阵列来揭示NFT形成的分子基础将需要具备以下知识:1)基因组学,2)AD, 3)细胞生物学,而候选人在这些领域几乎没有背景知识。拟议的计划将为候选人提供一段时间的指导研究,以获得这三个领域的专业知识。在此指导期间获得的专业知识将使候选人能够实现他的长期目标,即在神经科学领域发展独立的多学科研究事业,重点是神经退行性机制。本研究假设CD47信号通路导致AD患者tau代谢异常、NFT形成、神经元细胞死亡和痴呆。这一假设是通过严格的表达谱产生的,并将通过增加更多的AD病例进行分析,并通过显示正常、非痴呆对照不参与CD47信号级联来验证(Aim 1)。此后,我们建议在mRNA、蛋白和功能水平上验证这一途径(目的2)。重要的是,这些实验将确定许多新的和急需的潜在靶点来治疗阿尔茨海默病。Dietrich Stephan博士(导师)将提供基因组学和微阵列数据功能验证方面的培训。Joseph Rogers博士(联合导师)将提供AD和细胞生物学技术方面的培训。通过持续的合作(Dale Schenk和Michael Hutton),将获得病毒siRNA传递和tau细胞系以及磷酸化测定方面的额外资源和技术。TGen为候选人提供的许多资源,结合导师、共同导师和合作者的强大研究项目,将为候选人提供实现其职业目标所需的全面培训,并有望为与年龄相关的痴呆症的最大原因-阿尔茨海默病提供新的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TRAVIS L DUNCKLEY其他文献
TRAVIS L DUNCKLEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TRAVIS L DUNCKLEY', 18)}}的其他基金
DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease
DYRK1A 抑制作为阿尔茨海默病的新治疗方法
- 批准号:
10361451 - 财政年份:2020
- 资助金额:
$ 11.09万 - 项目类别:
DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease
DYRK1A 抑制作为阿尔茨海默病的新治疗方法
- 批准号:
9886310 - 财政年份:2020
- 资助金额:
$ 11.09万 - 项目类别:
DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease
DYRK1A 抑制作为阿尔茨海默病的新治疗方法
- 批准号:
10583561 - 财政年份:2020
- 资助金额:
$ 11.09万 - 项目类别:
Neurofibrillary Tangle-Induced Dementia in AD
AD 中神经原纤维缠结诱发的痴呆
- 批准号:
7187729 - 财政年份:2007
- 资助金额:
$ 11.09万 - 项目类别:
Neurofibrillary Tangle-Induced Dementia in AD
AD 中神经原纤维缠结诱发的痴呆
- 批准号:
7478399 - 财政年份:2007
- 资助金额:
$ 11.09万 - 项目类别:
Neurofibrillary Tangle-Induced Dementia in AD
AD 中神经原纤维缠结诱发的痴呆
- 批准号:
7365083 - 财政年份:2006
- 资助金额:
$ 11.09万 - 项目类别:
Neurofibrillary Tangle-Induced Dementia in AD
AD 中神经原纤维缠结诱发的痴呆
- 批准号:
7189070 - 财政年份:2006
- 资助金额:
$ 11.09万 - 项目类别:
Neurofibrillary Tangle-Induced Dementia in AD
AD 中神经原纤维缠结诱发的痴呆
- 批准号:
7576820 - 财政年份:2006
- 资助金额:
$ 11.09万 - 项目类别:
Neurofibrillary Tangle-Induced Dementia in AD
AD 中神经原纤维缠结诱发的痴呆
- 批准号:
7793369 - 财政年份:2006
- 资助金额:
$ 11.09万 - 项目类别:
Neurogenomics of Alzheimer's Disease and Aging
阿尔茨海默病和衰老的神经基因组学
- 批准号:
7272679 - 财政年份:2003
- 资助金额:
$ 11.09万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 11.09万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 11.09万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 11.09万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 11.09万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 11.09万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 11.09万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 11.09万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 11.09万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 11.09万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 11.09万 - 项目类别:














{{item.name}}会员




